2024. Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy. Biomolecules and Biomedicine. (Apr. 2024), 673–675. DOI:https://doi.org/10.17305/bb.2024.10641.